Things get interesting when we discover a patent which was filed by Sangamo in May 2017 titled “Targeted Treatment of Androgenic Alopecia.” As with virtually all patents, the lengthy text of the patent is difficult to read or to create a concise summary from. An intriguing aspect of this news is Sangamo works in several technology spaces, including previously mentioned genome editing and gene therapy, either would make an advanced type of hair growth therapy we have never seen before. One caveat to mention is the company’s pipeline does not currently display any indication for alopecia, meaning the therapy is not fully developed yet, so it will be some time before trials begin. We certainly hope to hear more from Sangamo Therapeutics as soon as possible about their interesting development for hair growth technology.
Sadick suggests avoiding “products with dyes and preservatives, like parabens and synthetic fragrances.” Ingredients that thicken the hair include amino acids, biotin, ginseng root, and menthol or peppermint oil — these are what you want to look for. “Amino acids provide the building blocks to build new strands, while biotin, part of the B-vitamin complex, is required by hair to metabolize amino acids and can help strengthen hair,” Sadick says. “Antioxidants such as vitamin E and ginseng are beneficial to promote hair growth because they reduce free radicals from sun, stress, or overprocessing and have anti-inflammatory properties.” Last but not least are the botanicals, which are great as they are rich in antioxidants and other compounds that stimulate blood flow and promote hair growth.
Other therapies for the treatment of alopecia areata include topical mid- to high-potency corticosteroids, minoxidil, anthralin, immunotherapy (diphenylcyclopropenone, squaric acid dibutylester), and systemic corticosteroids.12 Currently available therapies often yield unsatisfactory results, and some clinicians rely on the high rate of spontaneous remission or recommend a hairpiece or wig if remission does not occur.13
Joseph and his readership, he said, are convinced that we are at a “peak moment” for the industry. He ticked off “platelet-rich plasma” and “injectable cell therapies” and other high-level technologies that are being developed by companies from New York to San Diego, Tokyo, and Stockholm. He won’t make bets on who’s going to win the arms race. But, he says, “if you were the first, that’d be fun for the trillion dollars that you’d make. Over the next few years? It’s prime time.”
In this section we take a look at current hair loss cures in 2018. Using one or more of the treatments below is your best shot at keeping your hair around. However, if a cure is defined as a permanent fix to an ailment, these are far from that definition. Each of these treatments have their own limitations. Most are seen more as hair loss management treatments, rather than permanent hair loss cures.
Pfizer Reports Positive AA Trial Results – A JAK3 inhibitor and a tyrosine kinase inhibitor (TYK2/JAK1) have shown statistically significant results in a phase 2a trial conducted by Pfizer. The company announced the results on September 15, 2018 at the European Academy of Dermatology and Venerology Congress. Subjects of the trial received oral doses of the drugs over a 6 month period. The TYK2/JAK1 inhibitor showed the greater efficacy, improving hair regrowth by 49.5 points on the Severity of Alopecia Tool scale, compared to an improvement of 33.6 points by the JAK3 inhibitor. However, Pfizer has apparently decided to move forward with its JAK3 inhibitor due to 2 adverse events in the TYK2/JAK1 inhibitor cohort during the trial. Pfizer’s JAK3 candidate, PF-06651600, was also recently granted Breakthrough Designation from the US FDA for treating alopecia areata.
"Despite some of the claims, a shampoo or conditioner won’t be able to stop or slow hair loss, nor help with a receding hairline or thicken hair that’s becoming thinner," says trichologist Anabel Kingsley from The Philip Kingsley Trichology Clinic in London. "At best, a thickening shampoo will make hair temporarily thicker for a short period of time, but they certainly won’t help with hair loss or thinning."
Two clinical trials have been ran as a proof of concept for Histogen. Terminal hair count and hair thickness noticeably increased after just 12 weeks. Due to this success, Histogen plans to conduct a Phase 1 Clinical Study in the United States. This will be an injectable which when injected into the scalp will stimulate dormant hair follicles and induce new hair follicle formation (think Botox but for hair follicles instead of skin cells). HSC660 is an ongoing female hair loss trial that will run for 22 weeks and a late stage (Phase 3 trial) for men has initiated in Mexico. Histogen founder Gail Naughton even went so far to reveal commercialization, “We’e in very late-stage negotiations with some huge retail partners,” she says. It may not be a magic bullet, but it would sure be nice to have an alternative/supplement to Rogaine that actually stimulates growth.
Hair loss is not a hopeless condition. While there are certainly cases of permanent hair loss in men, there are still cases when it's only temporary and therefore can be treated, controlled and prevented. There are treatments and cures available, and many of these, especially those for temporary cases, can be as simple as lifestyle changes -- eating the right foods, learning to manage stress properly, and doing away with unhealthy, nasty habits that can aggravate the condition.
After the robot was done, two nurses picked off the skin grafts and hairs and put them in petri dishes. While they prepared them for implantation, Bernstein explained the real future of the business: cloning. Bernstein has partnered with a Columbia University geneticist, Angela Christiano, who is working on duplicating hairs. The problem with hair transplantation is that you’re moving hairs around, not creating new ones. Women affected by female-pattern hair loss, in particular, are left out: they don’t have a thick back patch of “donor hair” to work with.
Many pharmaceutical companies and researchers are in the search for a hair loss cure. This is because 7 out of 10 men and 4 out of 10 women suffer from androgenic alopecia (genetically caused hair loss) in their lifetime. In the United States that amounts to around 80 million men and 40 million women currently suffering from hair loss. Of course, a permanent cure would relieve a huge percentage of the population.
Pura d’or makes a very bold claim with this product: “continued use WILL prevent further hair loss.” While we doubt it will “prevent further hair loss” for everyone, it does have an all-star line up of ingredients. Even if it doesn’t completely stop hair loss, this organic shampoo is certainly the safest for your hair out of our top 5. This shampoo is designed for daily use.
Minoxidil is a similar treatment to finasteride and is also available in the UK as a generic or as the well known brand-name “Regaine”. Minoxidil can be bought over the counter, unlike Propecia or finasteride, and comes in the form of a lotion, foam or cream that is rubbed into the scalp every day. Minoxidil is less effective than finasteride (only 60% of men who used Regaine Extra Strength reported regrowth after 48 weeks) but is still a viable option for men seeking treatment. It is also suitable for use by women, and can be used to treat alopecia areata. However, as with finasteride, any beneficial effects will cease once treatment has stopped.
Telogen effluvium is a nonscarring, noninflammatory alopecia of relatively sudden onset, with similar incidences between sexes and age groups. It occurs when large numbers of hairs enter the telogen phase and fall out three to five months after a physiologic or emotional stressor. The list of inciting factors is extensive and includes severe chronic illnesses, pregnancy, surgery, high fever, malnutrition, severe infections, and endocrine disorders. Causative medications include retinoids, anticoagulants, anticonvulsants, beta blockers, and antithyroid medications; discontinuation of oral contraceptive agents is another possible cause.17
Trichotillomania may be difficult to diagnose if the patient is not forthcoming about pulling at his or her hair. Patients typically present with frontoparietal patches of alopecia that progress posteriorly and may include the eyelashes and eyebrows. Bare patches are typical, and the hair may appear uneven, with twisted or broken off hairs. Trichotillomania may lead to problems with self-esteem and social avoidance. Complications include infection, skin damage, and permanent scarring.18
“Curis (now-dormant company) had performed a lot of studies on targeting the Hedgehog pathway for hair growth with very promising results, however, their compounds caused orthosteric activation of the pathway (turning it on everywhere and robustly which is not safe) vs. Oxy133 which causes a much more regulated and limited allosteric activation of the pathway only in stem cells. This could make Oxy133 a blockbuster. Let’s see what happens.”
Dr. Hawkshaw and his team were lead to test WAY-316606 for hair growth after studying the effects of cyclosporine A (CsA) on hair growth. They found that CsA reduced the expression of SFRP1 in human hair follicles. After looking for other drug candidates that had a similar effect on SFRP1, WAY-316606 was identified. The team has already tested WAY-316606 on isolated human hair follicles which were donated from hair transplant surgeries, and plans to test the drug in human clinical trials in the future. A timeline for a human clinical trial has not been set yet, Follicle Thought will update this as news is presented.
A popular skin care drug—which is intended to target eczema—was just found to have an unusual side effect: hair growth. According to an article on Newsweek, the FDA-approved drug dupilumab was given to a 13-year-old alopecia sufferer to treat her eczema. The patient, who hadn’t grown hair on her scalp since she was two, suddenly grew a significant amount of hair on her head after continual use of the drug, a study in the journal JAMA Dermatology reports.